806 related articles for article (PubMed ID: 25445694)
21. MiR-152 and miR-185 co-contribute to ovarian cancer cells cisplatin sensitivity by targeting DNMT1 directly: a novel epigenetic therapy independent of decitabine.
Xiang Y; Ma N; Wang D; Zhang Y; Zhou J; Wu G; Zhao R; Huang H; Wang X; Qiao Y; Li F; Han D; Wang L; Zhang G; Gao X
Oncogene; 2014 Jan; 33(3):378-86. PubMed ID: 23318422
[TBL] [Abstract][Full Text] [Related]
22. Glabridin inhibits cancer stem cell-like properties of human breast cancer cells: An epigenetic regulation of miR-148a/SMAd2 signaling.
Jiang F; Li Y; Mu J; Hu C; Zhou M; Wang X; Si L; Ning S; Li Z
Mol Carcinog; 2016 May; 55(5):929-40. PubMed ID: 25980823
[TBL] [Abstract][Full Text] [Related]
23. Ultrasound reverses chemoresistance in breast cancer stem cell like cells by altering ABCG2 expression.
Guo L; Zheng P; Fan H; Wang H; Xu W; Zhou W
Biosci Rep; 2017 Dec; 37(6):. PubMed ID: 28935760
[TBL] [Abstract][Full Text] [Related]
24. ALDH1A isozymes are markers of human melanoma stem cells and potential therapeutic targets.
Luo Y; Dallaglio K; Chen Y; Robinson WA; Robinson SE; McCarter MD; Wang J; Gonzalez R; Thompson DC; Norris DA; Roop DR; Vasiliou V; Fujita M
Stem Cells; 2012 Oct; 30(10):2100-13. PubMed ID: 22887839
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of decitabine-loaded nanogels in overcoming cancer drug resistance is mediated via sustained DNA methyltransferase 1 (DNMT1) depletion.
Vijayaraghavalu S; Labhasetwar V
Cancer Lett; 2013 Apr; 331(1):122-9. PubMed ID: 23305699
[TBL] [Abstract][Full Text] [Related]
26. Breast cancer stem-like cells are inhibited by a non-toxic aryl hydrocarbon receptor agonist.
Prud'homme GJ; Glinka Y; Toulina A; Ace O; Subramaniam V; Jothy S
PLoS One; 2010 Nov; 5(11):e13831. PubMed ID: 21072210
[TBL] [Abstract][Full Text] [Related]
27. Doxorubicin and curcumin co-delivery by lipid nanoparticles for enhanced treatment of diethylnitrosamine-induced hepatocellular carcinoma in mice.
Zhao X; Chen Q; Li Y; Tang H; Liu W; Yang X
Eur J Pharm Biopharm; 2015 Jun; 93():27-36. PubMed ID: 25770771
[TBL] [Abstract][Full Text] [Related]
28. PGE
Lin MC; Chen SY; He PL; Herschman H; Li HJ
Int J Cancer; 2018 Sep; 143(6):1440-1455. PubMed ID: 29658109
[TBL] [Abstract][Full Text] [Related]
29. Cockle Shell-Derived Aragonite CaCO
Ibiyeye KM; Zuki ABZ
Int J Mol Sci; 2020 Mar; 21(5):. PubMed ID: 32164352
[TBL] [Abstract][Full Text] [Related]
30. Long-term exposure to estrogen enhances chemotherapeutic efficacy potentially through epigenetic mechanism in human breast cancer cells.
Chang YW; Singh KP
PLoS One; 2017; 12(3):e0174227. PubMed ID: 28323900
[TBL] [Abstract][Full Text] [Related]
31. Synergistic inhibition of breast cancer metastasis by silibinin-loaded lipid nanoparticles containing TPGS.
Xu P; Yin Q; Shen J; Chen L; Yu H; Zhang Z; Li Y
Int J Pharm; 2013 Sep; 454(1):21-30. PubMed ID: 23830941
[TBL] [Abstract][Full Text] [Related]
32. Pharmacologic reversion of epigenetic silencing of the PRKD1 promoter blocks breast tumor cell invasion and metastasis.
Borges S; Döppler H; Perez EA; Andorfer CA; Sun Z; Anastasiadis PZ; Thompson E; Geiger XJ; Storz P
Breast Cancer Res; 2013 Aug; 15(2):R66. PubMed ID: 23971832
[TBL] [Abstract][Full Text] [Related]
33. Altered DNA methylation is associated with docetaxel resistance in human breast cancer cells.
Kastl L; Brown I; Schofield AC
Int J Oncol; 2010 May; 36(5):1235-41. PubMed ID: 20372798
[TBL] [Abstract][Full Text] [Related]
34. Histone deacetylase (HDAC) inhibitors and doxorubicin combinations target both breast cancer stem cells and non-stem breast cancer cells simultaneously.
Hii LW; Chung FF; Soo JS; Tan BS; Mai CW; Leong CO
Breast Cancer Res Treat; 2020 Feb; 179(3):615-629. PubMed ID: 31784862
[TBL] [Abstract][Full Text] [Related]
35. IMD-0354 targets breast cancer stem cells: a novel approach for an adjuvant to chemotherapy to prevent multidrug resistance in a murine model.
Gomez-Cabrero A; Wrasidlo W; Reisfeld RA
PLoS One; 2013; 8(8):e73607. PubMed ID: 24014113
[TBL] [Abstract][Full Text] [Related]
36. ShRNA targeting Notch1 sensitizes breast cancer stem cell to paclitaxel.
Mao J; Song B; Shi Y; Wang B; Fan S; Yu X; Tang J; Li L
Int J Biochem Cell Biol; 2013 Jun; 45(6):1064-73. PubMed ID: 23500524
[TBL] [Abstract][Full Text] [Related]
37. FKBPL and its peptide derivatives inhibit endocrine therapy resistant cancer stem cells and breast cancer metastasis by downregulating DLL4 and Notch4.
McClements L; Annett S; Yakkundi A; O'Rourke M; Valentine A; Moustafa N; Alqudah A; Simões BM; Furlong F; Short A; McIntosh SA; McCarthy HO; Clarke RB; Robson T
BMC Cancer; 2019 Apr; 19(1):351. PubMed ID: 30975104
[TBL] [Abstract][Full Text] [Related]
38. Sabutoclax, pan-active BCL-2 protein family antagonist, overcomes drug resistance and eliminates cancer stem cells in breast cancer.
Hu Y; Yagüe E; Zhao J; Wang L; Bai J; Yang Q; Pan T; Zhao H; Liu J; Zhang J
Cancer Lett; 2018 Jun; 423():47-59. PubMed ID: 29496539
[TBL] [Abstract][Full Text] [Related]
39. Modulation of protein expression levels and DNA methylation status of breast cancer metastasis genes by anthracycline-based chemotherapy and the demethylating agent decitabine.
Ari F; Napieralski R; Ulukaya E; Dere E; Colling C; Honert K; Krüger A; Kiechle M; Schmitt M
Cell Biochem Funct; 2011 Dec; 29(8):651-9. PubMed ID: 21887697
[TBL] [Abstract][Full Text] [Related]
40. Zoledronic acid-encapsulating self-assembling nanoparticles and doxorubicin: a combinatorial approach to overcome simultaneously chemoresistance and immunoresistance in breast tumors.
Kopecka J; Porto S; Lusa S; Gazzano E; Salzano G; Pinzòn-Daza ML; Giordano A; Desiderio V; Ghigo D; De Rosa G; Caraglia M; Riganti C
Oncotarget; 2016 Apr; 7(15):20753-72. PubMed ID: 26980746
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]